ArticleJournal of clinical medicine2021
Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Efficacy and safety of tocilizumab in the treatment of Graves' orbitopathy: a systematic review and meta-analysis.BMC endocrine disorders · 2026Pooled it
- Immunomodulators in Graves' ophthalmopathy: a systematic review.Frontiers in endocrinology · 2026Pooled it
- Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis.Eye (London, England) · 2025Pooled it
- Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Development and validation of a nomogram for predicting non-response to tocilizumab in thyroid eye disease: a retrospective study.BMC ophthalmology · 2026Article
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2026Review
- [The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice].Problemy endokrinologii · 2026Article
- Sarilumab in the management of Graves orbitopathy with low clinical activity scores.Scientific reports · 2026Article
- Selective extraocular muscle regression following tocilizumab in active thyroid associated ophthalmopathy: a 3D MRI-based retrospective study.Frontiers in endocrinology · 2026Article
- Article
- Current concepts of tocilizumab efficacy in active moderate-to-severe corticosteroid-resistant cases of Graves' orbitopathy.Frontiers in endocrinology · 2025Review
- Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy.Frontiers in immunology · 2025Article
- Efficacy of Tocilizumab in Refractory Graves Orbitopathy From Real-World Clinical Practice: An Observational Study.Journal of the Endocrine Society · 2024Article
- A Chinese survey of clinical practice on the management of thyroid eye disease.European thyroid journal · 2024Article
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Smoking enhances proliferation, inflammatory markers, and immunoglobulins in peripheral blood mononuclear cells from Graves' patients.Endocrine connections · 2024Article
- Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort.International ophthalmology · 2024Article
- Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.Frontiers in endocrinology · 2024Article
- Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the effectiveness and safety of tocilizumab use for the treatment of active steroid-resistant Graves' orbitopathy (GO). A retrospective longitudinal study was conducted by reviewing the medical records at a single center between November 2009 and December 2018. A total of 114 patients with steroid-resistant Graves' orbitopathy were examined and treated with tocilizumab, of which 54 adults met the inclusion criteria. No concomitant medication for the treatment of orbitopathy was used. The main primary outcomes included changes from baseline in the Clinical Activity Score (CAS) and thyrotropin receptor antibody (TRAb) levels throughout therapy with tocilizumab. The absolute responses to treatment were defined as the achievement of CAS ≤ 1 and TRAb ≤ 10 U/L. A composite ophthalmic score including CAS, proptosis, eyelid retraction, and diplopia was used to evaluate individual improvement in GO. Adverse drug reactions were also assessed. Analysis of the patient's CAS and TRAb levels showed meaningful reductions during tocilizumab treatment. Differences between values at baseline and subsequent time points were statistically significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.